Evolent Health vs Huron Consulting
EVH and HURN side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVH and HURN compare
Huron Consulting is the larger company, worth 4.9 times as much as Evolent Health ($2.7B against $554M).
Evolent Health grew revenue faster over the last twelve months (14.1% versus 13.6% for Huron Consulting).
Huron Consulting keeps more of each dollar of sales as profit, with a net margin of 6.4% compared with −21.7% at Evolent Health.
Huron Consulting scores higher on the StockData Score (14 against 7 for Evolent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVH | HURN |
|---|---|---|
| Size and price | ||
| Market cap | $554M | $2.7B |
| Share price | $4.90 | $169.64 |
| Change, 1 year | 10.1% | 2.5% |
| Change, 5 years | −83.0% | 242% |
| Beta (5Y) | 0.82 | 0.47 |
| Employees | 4,200 | 305 |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 3 | 5 (better) |
| Performance score | 0 | 5 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.4× |
| P/S | 0.2× (better) | 1.5× |
| P/B | 1.5× (better) | 7.0× |
| EV/EBITDA | – | 15.6× |
| P/FCF | – | 16.8× |
| PEG | – | 1.49 |
| FCF yield | – | 6.0% |
| Fair value | $6.93 | $156.80 |
| Margin of safety | 29.3% (better) | −8.2% |
| Growth | ||
| Revenue growth (TTM) | 14.1% (better) | 13.6% |
| Revenue growth, 5Y average | 15.2% (better) | 14.3% |
| Net income growth (TTM) | – | 9.9% |
| EPS growth (TTM) | – | 16.4% |
| Profitability | ||
| Gross margin | 15.0% | 34.0% (better) |
| Operating margin | −18.5% | 10.3% (better) |
| Net margin | −21.7% | 6.4% (better) |
| FCF margin | – | 8.9% |
| Return on equity | −83.6% | 26.9% (better) |
| Return on invested capital | −23.0% | 12.3% (better) |
| Financial health | ||
| Debt / equity | 2.60 | 2.16 (better) |
| Net debt / EBITDA | – | 3.57 |
| Interest coverage | −6.2× | – |
| Current ratio | 1.26 | 1.71 (better) |
| Altman Z-score | −0.24 | 3.43 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.9% |
| Shareholder yield | 0.00% | 8.9% (better) |
| Ownership | ||
| Held by institutions | 99.3% | 99.3% |
| Held by insiders | 3.3% | 2.4% |
| Insider net buying, 12 months | −$329K (better) | −$6.4M |
| Short interest, % of float | 9.7% | 4.7% |
Go deeper
- EVH stock overview
- EVH income statement
- EVH valuation and score
- HURN stock overview
- HURN income statement
- HURN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.